Literature DB >> 33375151

Advances in Oral Subunit Vaccine Design.

Hans Van der Weken1, Eric Cox1, Bert Devriendt1.   

Abstract

Many pathogens invade the host at the intestinal surface. To protect against these enteropathogens, the induction of intestinal secretory IgA (SIgA) responses is paramount. While systemic vaccination provides strong systemic immune responses, oral vaccination is the most efficient way to trigger protective SIgA responses. However, the development of oral vaccines, especially oral subunit vaccines, is challenging due to mechanisms inherent to the gut. Oral vaccines need to survive the harsh environment in the gastrointestinal tract, characterized by low pH and intestinal proteases and need to reach the gut-associated lymphoid tissues, which are protected by chemical and physical barriers that prevent efficient uptake. Furthermore, they need to surmount default tolerogenic responses present in the gut, resulting in suppression of immunity or tolerance. Several strategies have been developed to tackle these hurdles, such as delivery systems that protect vaccine antigens from degradation, strong mucosal adjuvants that induce robust immune responses and targeting approaches that aim to selectively deliver vaccine antigens towards specific immune cell populations. In this review, we discuss recent advances in oral vaccine design to enable the induction of robust gut immunity and highlight that the development of next generation oral subunit vaccines will require approaches that combines these solutions.

Entities:  

Keywords:  Micro- and nanoparticles; adjuvants; mucosal immunity; oral vaccination; secretory IgA; subunit vaccines; targeted delivery

Year:  2020        PMID: 33375151      PMCID: PMC7822154          DOI: 10.3390/vaccines9010001

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  251 in total

Review 1.  Novel adenovirus vector-based vaccines for HIV-1.

Authors:  Dan H Barouch
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

2.  Retinoic acid modulates IL-5 receptor expression and selectively inhibits eosinophil-basophil differentiation of hemopoietic progenitor cells.

Authors:  John W Upham; Roma Sehmi; Lisa M Hayes; Karen Howie; Joachim Lundahl; Judah A Denburg
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

3.  DNA degradation and its defects.

Authors:  Kohki Kawane; Kou Motani; Shigekazu Nagata
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-06-02       Impact factor: 10.005

4.  The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system.

Authors:  K A Papadakis; J Prehn; V Nelson; L Cheng; S W Binder; P D Ponath; D P Andrew; S R Targan
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

5.  Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression.

Authors:  Sheng Xiao; Hulin Jin; Thomas Korn; Sue M Liu; Mohamed Oukka; Bing Lim; Vijay K Kuchroo
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

6.  Oral immunization with Lactococcus lactis-expressing EspB induces protective immune responses against Escherichia coli O157:H7 in a murine model of colonization.

Authors:  B Ahmed; M Loos; D Vanrompay; E Cox
Journal:  Vaccine       Date:  2014-05-28       Impact factor: 3.641

7.  Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis.

Authors:  Deepak B Rawool; Constantine Bitsaktsis; Ying Li; Diane R Gosselin; Yili Lin; Nitin V Kurkure; Dennis W Metzger; Edmund J Gosselin
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

8.  Environmental Enteropathy, Oral Vaccine Failure and Growth Faltering in Infants in Bangladesh.

Authors:  Caitlin Naylor; Miao Lu; Rashidul Haque; Dinesh Mondal; Erica Buonomo; Uma Nayak; Josyf C Mychaleckyj; Beth Kirkpatrick; Ross Colgate; Marya Carmolli; Dorothy Dickson; Fiona van der Klis; William Weldon; M Steven Oberste; Jennie Z Ma; William A Petri
Journal:  EBioMedicine       Date:  2015-09-25       Impact factor: 8.143

9.  Race-related differences in antibody responses to the inactivated influenza vaccine are linked to distinct pre-vaccination gene expression profiles in blood.

Authors:  Raj Kurupati; Andrew Kossenkov; Larissa Haut; Senthil Kannan; Zhiquan Xiang; Yan Li; Susan Doyle; Qin Liu; Kenneth Schmader; Louise Showe; Hildegund Ertl
Journal:  Oncotarget       Date:  2016-09-27

Review 10.  The Impact of the Microbiome on Immunity to Vaccination in Humans.

Authors:  Sanne E de Jong; Axel Olin; Bali Pulendran
Journal:  Cell Host Microbe       Date:  2020-08-12       Impact factor: 21.023

View more
  8 in total

1.  Oral vaccination with recombinant Lactobacillus casei expressing Aha1 fused with CTB as an adjuvant against Aeromonas veronii in common carp (Cyprinus carpio).

Authors:  Chong Chen; Shuo Zu; Dongxing Zhang; Zelin Zhao; Yalu Ji; Hengyu Xi; Xiaofeng Shan; Aidong Qian; Wenyu Han; Jingmin Gu
Journal:  Microb Cell Fact       Date:  2022-06-13       Impact factor: 6.352

Review 2.  Mucosal Vaccination Against Periodontal Disease: Current Status and Opportunities.

Authors:  Victor Vaernewyck; Boaz Arzi; Niek N Sanders; Eric Cox; Bert Devriendt
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

Review 3.  Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic.

Authors:  Samagra Jain; Abhijeet Venkataraman; Marissa E Wechsler; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2021-10-09       Impact factor: 17.873

4.  Bacterial Ghosts of Pseudomonas aeruginosa as a Promising Candidate Vaccine and Its Application in Diabetic Rats.

Authors:  Salah A Sheweita; Amro A Amara; Heba Gamal; Amany A Ghazy; Ahmed Hussein; Mohammed Bahey-El-Din
Journal:  Vaccines (Basel)       Date:  2022-06-07

Review 5.  Extracellular Polymeric Substances: Still Promising Antivirals.

Authors:  Raquel Bello-Morales; Sabina Andreu; Vicente Ruiz-Carpio; Inés Ripa; José Antonio López-Guerrero
Journal:  Viruses       Date:  2022-06-19       Impact factor: 5.818

Review 6.  Recent Advances and Future Perspectives in Polymer-Based Nanovaccines.

Authors:  Natassa Pippa; Maria Gazouli; Stergios Pispas
Journal:  Vaccines (Basel)       Date:  2021-05-26

Review 7.  A review of the antiviral activity of Chitosan, including patented applications and its potential use against COVID-19.

Authors:  Nisrein Jaber; Mayyas Al-Remawi; Faisal Al-Akayleh; Najah Al-Muhtaseb; Ibrahim S I Al-Adham; Phillip J Collier
Journal:  J Appl Microbiol       Date:  2021-07-26       Impact factor: 4.059

8.  Antibody-Mediated Targeting of Antigens to Intestinal Aminopeptidase N Elicits Gut IgA Responses in Pigs.

Authors:  Hans Van der Weken; Raquel Sanz Garcia; Niek N Sanders; Eric Cox; Bert Devriendt
Journal:  Front Immunol       Date:  2021-10-14       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.